{"publication_id":"d4f00c86-0bac-4793-bea2-326eac5529d0","content_hash":"sha256:6dcb044173b176c73c7c0a394b197f6e2dd2b4c7f9b13b0a1cd42cefd41eeafd","nodes":[{"id":"d4f00c86-0bac-4793-bea2-326eac5529d0","type":"publication","title":"GLP 1: Gastrointestinal adverse events were more frequent with semaglutide (82.8%) vs placebo (63.2%)"},{"id":"claim_1","type":"claim","text":"The cited direct receipts support a bounded working claim: Gastrointestinal adverse events were more frequent with semaglutide (82.8%) vs placebo (63.2%); Gastrointestinal events were reported in 49.1% of participants who continued subcutaneous semaglutide vs 26.1% with placebo."},{"id":"claim_2","type":"claim","text":"Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication."},{"id":"claim_3","type":"claim","text":"Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?"},{"id":"claim_4","type":"claim","text":"_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._"},{"id":"claim_5","type":"claim","text":"`fact_id=139252` (`A_core`) — The incidence of thyroid cancer in semaglutide-treated patients was less than 1%, suggesting no significant risk. Source: Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Sys"},{"id":"source_1","type":"source","study":"Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial","year":2021,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_2","type":"source","study":"Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial","year":2021,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_3","type":"source","study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","year":2022,"doi":"10.1038/s41591-022-02026-4","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_4","type":"source","study":"Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials","year":2024,"doi":"10.1111/obr.13792","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_5","type":"source","study":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","year":2024,"doi":"10.1038/s41591-024-03015-5","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"}],"edges":[{"from":"d4f00c86-0bac-4793-bea2-326eac5529d0","to":"claim_1","type":"contains_claim"},{"from":"d4f00c86-0bac-4793-bea2-326eac5529d0","to":"claim_2","type":"contains_claim"},{"from":"d4f00c86-0bac-4793-bea2-326eac5529d0","to":"claim_3","type":"contains_claim"},{"from":"d4f00c86-0bac-4793-bea2-326eac5529d0","to":"claim_4","type":"contains_claim"},{"from":"d4f00c86-0bac-4793-bea2-326eac5529d0","to":"claim_5","type":"contains_claim"}],"screening":{"identified":5,"screened":5,"excluded":0,"included":5,"included_or_retained":5,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}